These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33844524)

  • 1. Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360.
    Rueeger H; Lueoend R; Machauer R; Veenstra SJ; Holzer P; Hurth K; Voegtle M; Frederiksen M; Rondeau JM; Tintelnot-Blomley M; Jacobson LH; Staufenbiel M; Laue G; Neumann U
    J Med Chem; 2021 Apr; 64(8):4677-4696. PubMed ID: 33844524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.
    Machauer R; Lueoend R; Hurth K; Veenstra SJ; Rueeger H; Voegtle M; Tintelnot-Blomley M; Rondeau JM; Jacobson LH; Laue G; Beltz K; Neumann U
    J Med Chem; 2021 Oct; 64(20):15262-15279. PubMed ID: 34648711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.
    Anan K; Iso Y; Oguma T; Nakahara K; Suzuki S; Yamamoto T; Matsuoka E; Ito H; Sakaguchi G; Ando S; Morimoto K; Kanegawa N; Kido Y; Kawachi T; Fukushima T; Teisman A; Urmaliya V; Dhuyvetter D; Borghys H; Austin N; Van Den Bergh A; Verboven P; Bischoff F; Gijsen HJM; Yamano Y; Kusakabe K
    ChemMedChem; 2019 Nov; 14(22):1894-1910. PubMed ID: 31657130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
    Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central Aβ reduction.
    Nakahara K; Mitsuoka Y; Kasuya S; Yamamoto T; Yamamoto S; Ito H; Kido Y; Kusakabe KI
    Eur J Med Chem; 2021 Apr; 216():113270. PubMed ID: 33765486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.
    Pettus LH; Bourbeau MP; Bradley J; Bartberger MD; Chen K; Hickman D; Johnson M; Liu Q; Manning JR; Nanez A; Siegmund AC; Wen PH; Whittington DA; Allen JR; Wood S
    J Med Chem; 2020 Mar; 63(5):2263-2281. PubMed ID: 31589043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects.
    Neumann U; Machauer R; Shimshek DR
    Br J Pharmacol; 2019 Sep; 176(18):3435-3446. PubMed ID: 30657591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.
    Veenstra SJ; Rueeger H; Voegtle M; Lueoend R; Holzer P; Hurth K; Tintelnot-Blomley M; Frederiksen M; Rondeau JM; Jacobson L; Staufenbiel M; Neumann U; Machauer R
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2195-2200. PubMed ID: 29764741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
    Hilpert H; Guba W; Woltering TJ; Wostl W; Pinard E; Mauser H; Mayweg AV; Rogers-Evans M; Humm R; Krummenacher D; Muser T; Schnider C; Jacobsen H; Ozmen L; Bergadano A; Banner DW; Hochstrasser R; Kuglstatter A; David-Pierson P; Fischer H; Polara A; Narquizian R
    J Med Chem; 2013 May; 56(10):3980-95. PubMed ID: 23590342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization.
    Nakahara K; Fuchino K; Komano K; Asada N; Tadano G; Hasegawa T; Yamamoto T; Sako Y; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jul; 61(13):5525-5546. PubMed ID: 29775538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.
    Cumming JN; Smith EM; Wang L; Misiaszek J; Durkin J; Pan J; Iserloh U; Wu Y; Zhu Z; Strickland C; Voigt J; Chen X; Kennedy ME; Kuvelkar R; Hyde LA; Cox K; Favreau L; Czarniecki MF; Greenlee WJ; McKittrick BA; Parker EM; Stamford AW
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2444-9. PubMed ID: 22390835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
    Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
    J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial.
    Koriyama Y; Hori A; Ito H; Yonezawa S; Baba Y; Tanimoto N; Ueno T; Yamamoto S; Yamamoto T; Asada N; Morimoto K; Einaru S; Sakai K; Kanazu T; Matsuda A; Yamaguchi Y; Oguma T; Timmers M; Tritsmans L; Kusakabe KI; Kato A; Sakaguchi G
    J Med Chem; 2021 Feb; 64(4):1873-1888. PubMed ID: 33588527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
    Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT
    J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
    May PC; Willis BA; Lowe SL; Dean RA; Monk SA; Cocke PJ; Audia JE; Boggs LN; Borders AR; Brier RA; Calligaro DO; Day TA; Ereshefsky L; Erickson JA; Gevorkyan H; Gonzales CR; James DE; Jhee SS; Komjathy SF; Li L; Lindstrom TD; Mathes BM; Martényi F; Sheehan SM; Stout SL; Timm DE; Vaught GM; Watson BM; Winneroski LL; Yang Z; Mergott DJ
    J Neurosci; 2015 Jan; 35(3):1199-210. PubMed ID: 25609634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly Selective and Potent Human β-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies.
    Ghosh AK; Brindisi M; Yen YC; Lendy EK; Kovela S; Cárdenas EL; Reddy BS; Rao KV; Downs D; Huang X; Tang J; Mesecar AD
    ChemMedChem; 2019 Mar; 14(5):545-560. PubMed ID: 30637955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.
    Gijsen HJM; Alonso de Diego SA; De Cleyn M; García-Molina A; Macdonald GJ; Martínez-Lamenca C; Oehlrich D; Prokopcova H; Rombouts FJR; Surkyn M; Trabanco AA; Van Brandt S; Van den Bossche D; Van Gool M; Austin N; Borghys H; Dhuyvetter D; Moechars D
    J Med Chem; 2018 Jun; 61(12):5292-5303. PubMed ID: 29809004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.